M.D. Fudan University Medical School, Shanghai, China
M.S. Fudan University Medical School, Shanghai, China (Pharmacology)
Ph.D. Academy of Military Medical Sciences, Beijing, China (Pharmacology)
NIH/NIDA INVEST Research Fellow University of California San Francisco, California
Dr. Wang received her MD degree from Fudan University Medical School and her Ph.D from the Academy of Military Medical Science in Beijing. She did postdoctoral training at the University of California San Francisco. She was a Research Assistant Professor at Ohio State University, Department of Cancer Biology and Genetics and Associate Director of Center for Pharmacogenomics prior to joining the University of Florida.
Dr. Wang’s research interests are the discovery of genetic biomarkers for personalized drug therapy. She has discovered many functional regulatory variants in genes related to drug therapy in the areas of cardiovascular diseases, mental diseases and drug dependence. Some of these functional variants are currently included in biomarker testing panels to predict drug response.
Funded by NIH R01 award, “Expression genetics of CYP3A drug metabolizing enzymes”, Dr. Wang’s current research is to understand factors controlling the expression of CYP3A, the main drug metabolizing enzyme in the liver. Using recently developed cutting edge functional genetics/genomics approaches, the research will focus on understanding what genetic, epigenetic and non-genetic factors may contribute to CYP3A variability, with the goal to identify biomarker predicting CYP3A enzyme activity for personalized therapy of nearly 50% of currently used medications.
Dr. Wang has served as an Associate Editor of “European Journal of Pharmaceutical Sciences” and was on editorial Board of “Journal of Pharmacogenomics and Pharmacoproteomics”. She has also served as grant reviewer for NIH.
American Society for Human Genetics (ASHG)
American Society of Pharmacology Experimental Therapeutics (ASPET)
International Society for the Study of Xenobiotics (ISSX)
Pharmacogenomics Research Network (PGRN)
(1) D. Wang, Y. Guo, S.A. Wrighton, G.E. Cooke and W. Sadee. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. The Pharmacogenomics J. 11(4):274-286, 2011, PMID 20386561, PMC3248744
(2) D. Wang, M.J Poi, X. Sun, A. Gaedigk, J.S. Leeder, W. Sadee. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Human Molecular Genetics, 23(1): 268-278, 2014. PMID: 23985325, PMC3857955
(3) D. Wang, A.C Papp, X. Sun. Functional characterization of CYP2D6 enhancer polymorphisms. Human Molecular Genetics, 24:1556-1562, 2014. PMID: 25381333, PMC4381757
4) D. Wangand W. Sadee. CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. Pharmacogenetics and Genomics. 26:40-43, 2016, PMID: 26488616, PMCID: PMC4674354
(5) L. Li, L. Zhang, P.F. Binkley, W. Sadee and D. Wang. Regulatory variants modulate protein kinase C alpha (PRKCA) gene expression in human heart. Pharm Res. 34:1648-1657, 2017. PMID: 28120175